Valuation: Orexo AB

Market Cap 50.57M 5.18M 4.61M 4.23M 3.84M 7.23M 489M 7.39M 20.27M 259M 19.43M 19.02M 820M P/E 2024
-2.97x
P/E 2025 1.63x
Enterprise Value -370M -37.92M -33.79M -30.99M -28.16M -52.94M -3.58B -54.14M -148M -1.9B -142M -139M -6.01B EV / Sales 2024
1.62x
EV / Sales 2025 23.8x
Free-Float
78.37%
Yield 2024 *
-
Yield 2025 -
1 day-3.34%
1 week-69.29%
Current month-69.16%
1 month-89.19%
3 months-90.15%
6 months-92.22%
Current year-95.19%
1 week 1.3
Extreme 1.3
4.92
1 month 1.3
Extreme 1.3
9.02
Current year 1.3
Extreme 1.3
36
1 year 1.3
Extreme 1.3
36
3 years 1.3
Extreme 1.3
43.4
5 years 1.3
Extreme 1.3
43.4
10 years 1.3
Extreme 1.3
87.9
Manager TitleAgeSince
Chief Executive Officer 54 2013-02-04
Director of Finance/CFO 59 2022-08-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 64 2001-12-31
Director/Board Member 70 2019-04-10
Director/Board Member 62 2022-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/25 Buy

Chief Executive Officer

6 0.0000%
9/4/25 Free

Chief Executive Officer

1,393 0.0040%
9/3/25 Free 149 0.0004% -
Change 5-day change 1-year change 3-year change Capi.($)
-3.34%-69.29%-94.64%-90.65% 5.65M
+0.61%+10.07%+56.36%+149.73% 1,255B
+3.81%+1.95%+47.88%+82.58% 641B
+3.09%+3.09%+36.56%+108.48% 505B
+1.25%-0.73%+49.96%+66.87% 381B
+3.93%+6.69%+79.30%+45.44% 357B
+2.10%+3.90%+32.30%+61.10% 303B
+1.92%+9.87%+11.94%+36.55% 286B
+3.73%+5.90%+61.27%+77.31% 249B
+4.19%+9.60%+41.85%+113.85% 208B
Average +2.13%-2.20%+32.28%+65.13% 418.52B
Weighted average by Cap. +2.30%+5.74%+48.84%+97.79%

Financials

2024 2025
Net sales 590M 60.41M 53.83M 49.36M 44.86M 84.33M 5.71B 86.26M 237M 3.02B 227M 222M 9.57B 26M 2.66M 2.37M 2.18M 1.98M 3.72M 252M 3.8M 10.42M 133M 9.99M 9.78M 422M
Net income -203M -20.78M -18.52M -16.98M -15.44M -29.02M -1.96B -29.68M -81.38M -1.04B -78.01M -76.34M -3.29B 639M 65.45M 58.33M 53.49M 48.61M 91.38M 6.19B 93.47M 256M 3.27B 246M 240M 10.37B
Net Debt 353M 36.11M 32.18M 29.51M 26.82M 50.42M 3.41B 51.57M 141M 1.81B 136M 133M 5.72B -421M -43.09M -38.4M -35.22M -32M -60.16M -4.07B -61.54M -169M -2.16B -162M -158M -6.83B
Projected Income Statement - Annual - Orexo AB
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
55
Date Price Change Volume
26-11-04 SEK 1.448 -3.34% 801,095
26-11-03 SEK 1.498 -64.38% 4,013,077
26-11-02 SEK 4.205 -10.44% 230,073
26-10-30 SEK 4.695 +2.18% 81,224
26-10-29 SEK 4.595 -2.55% 369,430
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Orexo AB

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Orexo AB